Kedrion Biopharma
Dmitry Simkhovich serves as the Global Head of Business Intelligence at Kedrion Biopharma, overseeing strategic initiatives and reporting directly to the Chief Commercial Officer. Since joining Kedrion Biopharma in July 2016, Dmitry has held various leadership roles, including Director of Strategic Pricing and Commercial Insights, and has played a pivotal role in the merger of Kedrion and BPL legacy companies. Dmitry's prior experience includes senior management positions focused on commercial excellence and financial success in the U.S. market, where significant contributions were made to enhance EBITDA and operational effectiveness. Dmitry's career began at Eisai and includes a role as an Operations Business Analyst at KEDPLASMA, demonstrating a strong foundation in finance and strategic planning. Dmitry earned both a Bachelor’s Degree in Finance and an MBA in Financial Management from Iona University.
This person is not in any teams
This person is not in any offices
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.